Pluristem Therapeutics, Inc. (PSTI)
| Market Cap | 202.25M |
| Revenue (ttm) | 23,000 |
| Net Income (ttm) | -30.50M |
| Shares Out | 25.54M |
| EPS (ttm) | -1.47 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 20 |
| Last Price | $7.89 |
| Previous Close | $7.87 |
| Change ($) | 0.02 |
| Change (%) | 0.25% |
| Day's Open | 8.08 |
| Day's Range | 7.80 - 8.19 |
| Day's Volume | 546,484 |
| 52-Week Range | 2.89 - 12.43 |
HAIFA, Israel, Dec. 29, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therap...
HAIFA, Israel, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. ( Nasdaq:PSTI ) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological ther...
Pluristem's CLI Phase III trial interim results should be published soon. Results are critical and might define the fate of the company.
HAIFA, Israel, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. ( Nasdaq:PSTI ) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological ther...
HAIFA, Israel, Oct. 20, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. ( Nasdaq:PSTI ) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological prod...
Two new sample breakout stocks for Week 43 with better than 10% short-term upside potential. Now up an average +241.2% YTD.
Investors need to pay close attention to Pluristem Therapeutics (PSTI) stock based on the movements in the options market lately.
Reports internal efficacy and safety data from first cohort Reports internal efficacy and safety data from first cohort
HAIFA, Israel, Oct. 07, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. ( Nasdaq:PSTI ) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological ther...
HAIFA, Israel, Sept. 15, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biologica...
HAIFA, Israel, Aug. 27, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological...
Pluristem (PSTI) completes enrollment in the phase I study in patients with complete hematopoietic recovery following hematopoietic cell transplantation in the United States and Israel.
Top line efficacy results expected Q1 2021 Top line efficacy results expected Q1 2021
HAIFA, Israel, July 21, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological...
HAIFA, Israel, June 11, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological...
HAIFA, Israel, June 03, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological...
Is (PSTI) Outperforming Other Medical Stocks This Year?
Pluristem Therapeutics: The Search For An ARDS Treatment, And Whether Its Growth Will Continue
Is (PSTI) Outperforming Other Medical Stocks This Year?
Update is provided in advance of the company’s recruitment of first patient for its phase II Covid-19 study Update is provided in advance of the company’s recruitment of first patient for its ...
HAIFA, Israel, May 08, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological ...
HAIFA, Israel, May 05, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological th...
As of late, it has definitely been a great time to be an investor in Pluristem Therapeutics Inc. (PSTI).
Does Pluristem (PSTI) have what it takes to be a top stock pick for momentum investors? Let's find out.
• Elaborating on agreement terms and tranches schedule • Provides update on cash position and clinical program
HAIFA, Israel, April 30, 2020 (GLOBE NEWSWIRE) --
Promising results from a very small study caused shares of stem cell stocks to soar, but investors shouldn't get too carried away just yet.
The stem cell developer found a financing solution that won't dilute shareholders. Well, not immediately, anyway.
EXPECTED ONLINE SIGNING CEREMONY ON APRIL 30, 2020 EXPECTED ONLINE SIGNING CEREMONY ON APRIL 30, 2020
Orgenesis Acquiring Tamir, And Other News: The Good, Bad And Ugly Of Biopharma
Pluristem (PSTI) gains on the treatment of first patient suffering from COVID-19 complications with its cell therapy.
With the coronavirus outbreak gaining steam worldwide, pharma/biotech companies are evaluating every possible therapy to combat the spread.
HAIFA, Israel, April 13, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological ...
Investors need to pay close attention to Pluristem (PSTI) stock based on the movements in the options market lately.
Pluristem Therapeutics (NASDAQ: PSTI) shares are trading higher on Tuesday, after the company reported preliminary data from its coronavirus compassionate use program, treating seven patients ...
HAIFA, Israel, April 07, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biologica...
HAIFA, Israel, March 30, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biologica...
HAIFA, Israel, March 26, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological pr...
HAIFA, Israel, March 12, 2020 (GLOBE NEWSWIRE) -- HAIFA, Israel, March 12, 20 20 - Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company deve...
HAIFA, Israel, Feb. 10, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel cell thera...
HAIFA, Israel, Feb. 03, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological...
Patients unsuitable for revascularization surgery currently have no alternative treatments, leading to high risk of leg amputation and death; PLX-PAD may become the first drug approved to trea...
As of late, it has definitely been a great time to be an investor Pluristem Therapeutics.
Multinational study in the U.S., Israel and Europe targeting to be the first product candidate supporting muscle regeneration after significant trauma such as hip fracture Multinational study ...
HAIFA, Israel, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy...
Pluristem Therapeutics has been struggling lately, but the selling pressure may be coming to an end soon.
HAIFA, Israel, Sept. 16, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc . (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy...
Data readout from second cohort of hematological study will be presented Call scheduled for Monday, September 16 at 10:00am ET Data readout from second cohort of hematological study will be pr...
HAIFA, Israel, Aug. 21, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy...
About PSTI
Pluristem Therapeutics, together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD cells, which is Phase III clinical trial for the treatment of critical limb ischemia (CLI) in pa... [Read more...]
| Industry Biotechnology | Founded 2001 |
| CEO Yaky Yanay | Employees 146 |
| Stock Exchange NASDAQ | Ticker Symbol PSTI |
Financial Performance
In 2020, PSTI's revenue was $23,000, a decrease of -57.41% compared to the previous year's $54,000. Losses were -$29.15 million, -17.43% less than in 2019.
Analyst Forecasts
According to 4 analysts, the average rating for PSTI stock is "Buy." The 12-month stock price forecast is 8.60, which is an increase of 9.00% from the latest price.